« Home

Home » Chemistry » Patrick: An Introduction to Medicinal Chemistry 4e » Student resources » Hyperlinked bibliography » Chapter 20

Patrick: An Introduction to Medicinal Chemistry 4e

Chapter 20

Further reading

Carr, A. (2003) Toxicity of antiretroviral therapy and implications for drug development. Nature Reviews Drug Discovery, 2, 624-634 [DOI: 10.1038/nrd1151] [PubMed: 12904812].

Coen, D. M., and Schaffer, P. A. (2003) Antiherpesvirus drugs: a promising spectrum of new drugs and drug targets. Nature Reviews Drug Discovery, 2, 278-288 [DOI: 10.1038/nrd1065] [PubMed: 12669027].

De Clercq, E. (2002) Strategies in the design of antiviral drugs. Nature Reviews Drug Discovery, 1, 13-25 [DOI: 10.1038/nrd703] [PubMed: 12119605].

Driscoll, J. S. (2002) Antiviral agents. Ashgate, Aldershot.

Greer, J., Erickson, J. W., Baldwin, J. J., and Varney, M. D. (1994) Application of the three-dimensional structures of protein target molecules in structure-based design. Journal of Medicinal Chemistry, 37, 1035-1054 [DOI: 10.1021/jm00034a001] [PubMed: 8164249].

Milroy, D., and Featherstone, J. (2002) Antiviral market overview. Nature Reviews Drug Discovery, 1, 11-12 [DOI: 10.1038/nrd709] [PubMed: 12119604].

Tan, S-L., et al. (2002) Hepatitis C therapeutics: current status and emerging strategies. Nature Reviews Drug Discovery, 1, 867-881 [DOI: 10.1038/nrd937] [PubMed: 12415247].

HIV, Beaulieu, P. R., et al.. (2000). Journal of Medicinal Chemistry, 43, 1094-1108 (palinavir).

Campiani, G., et al. (2002) Non-nucleoside HIV-1 reverse transcriptase (RT) inhibitors: past, present and future perspectives. Current Pharmaceutical Design, 8, 615-657 [DOI: 10.2174/1381612024607207] [PubMed: 11945162].

De Clercq, E. (2003) The bicyclam AMD3100 story. Nature Reviews Drug Discovery, 2, 581-587 [DOI: 10.1038/nrd1134] [PubMed: 12815382].

Dubey, S.Satyanarayana, Y. D., and Lavinia, H. (2007) Development of integrase inhibitors for treatment of AIDS: An overview. European Journal of Medicinal Chemistry, 42, 1159-1168 [DOI: 10.1016/j.ejmech.2007.01.024].

Ghosh, A. K., Dawson, Z. L., and Mitsuya, H. Darunavir, a conceptually new HIV-1 protease inhibitor for the treatment of drug-resistant HIV. Bioorganic and Medicinal Chemistry, 15, 7576-7580 [DOI: 10.1016/j.bmc.2007.09.010] [PubMed: 17900913].

HIV databases http://www.hiv.lanl.gov/content/index.

Kempf, D. J., and Sham, H. L. (1996) Protease inhibitors. Current Pharmaceutical Design, 2, 225-246.

Matthews, T., et al. (2004) Enfuvirtide: the first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes. Nature Reviews Drug Discovery, 3, 215-225 [DOI: 10.1038/nrd1331] [PubMed: 15031735].

Miller, J. F., Furfine, E. S., Hanlon, M. H., et al. (2004) Novel arylsulfonamides possessing sub-picomolar HIV protease activities and potent anti-HIV activity against wild-type and drug-resistant viral strains. Bioorganic and Medical. Chemistry Letters, 14, 959-963 [DOI: 10.1016/j.bmcl.2003.12.008] (amprenavir).

Price, D. A., et al. (2006) Overcoming HERG affinity in the discovery of the CCR5 antagonist maraviroc. Bioorganic and Medicinal Chemistry Letters, 16, 4633-4637 [DOI: 10.1016/j.bmcl.2006.06.012] [PubMed: 16782336].

Raja, A., Lebbos, J., and Kirkpatrick, P. (2003) Atazanavir sulphate. Nature Reviews Drug Discovery, 2, 857-858 [DOI: 10.1038/nrd1232] [PubMed: 14702957].

Tomasselli, A. G. and Heinrikson, R. L. (2000) Targeting the HIV-protease in AIDS therapy. Biochimica et Biophysica Acta, 1477, 189-214 [PubMed: 10708858].

Tomasselli, A. G., Thaisrivongs, S., and Heinrikson, R. L. (1996) Discovery and design of HIV protease inhibitors as drugs for AIDS. Advances in Antiviral Drug Design, 2, 173-228 [DOI: 10.1016/S1075-8593(96)80106-7].

Werber, Y. (2003) HIV drug market. Nature Reviews Drug Discovery, 2, 513-514 [DOI: 10.1038/nrd1135] [PubMed: 12841188].

Flu Babu, Y. S., Chand, P., Bantia, S., et al. (2000) Discovery of a novel, highly potent, orally active, and selective influenza neuraminidase inhibitor through structure-based drug design. Journal of Medicinal Chemistry, 43, 3482-3486 [DOI: 10.1021/jm0002679] [PubMed: 11000002].

Ezzell, C. (2001) Magic bullets fly again. Scientific American, October, 28-35 (antibodies).

Kim, C. U., Lew, W., Williams. M. A., et al. (1998) Structure-activity relationship studies of novel carbocyclic influenza neuraminidase inhibitors. Journal of Medicinal Chemistry, 41, 2451-2460 [DOI: 10.1021/jm980162u] [PubMed: 9651151] (oseltamivir).

Laver, W. G., Bischofberger, N., and Webster, R. G. (1999) Disarming flu viruses. Scientific American, January, 56-65.

Taylor, N. R., Cleasby, A., Singh, O., et al. (1998) Dihydropyrancarboxamides related to zanamivir: a new series of inhibitors of influenza virus sialidases. 2. crystallographic and molecular modeling study of complexes of 4-amino-4H-pyran-6-carboxamides and sialidase from influenza virus types A and B. Journal of Medicinal Chemistry, 41, 798-807 [DOI: 10.1021/jm9703754] [PubMed: 9526556] (carboxamides).

von Itzstein, M., Dyason, J. C., Oliver, S. W., et al. (1996) A study of the active site of influenza virus sialidase: an approach to the rational design of novel antiinfluenza drugs. Journal of Medicinal Chemistry, 39, 388-391 [DOI: 10.1021/jm950294c] (zanamivir).